.jpg)
1 hour ago
3
Article content
- The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cells
- Deal includes upfront and milestone payments to Sitryx totaling over US $500 million, plus tiered royalties
- Exclusive license expands Boehringer’s preclinical immunology pipeline aiming to improve patient outcomes
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Ingelheim, Germany, Oxford, UK and Boston, USA, 26, February 2026 – Boehringer Ingelheim and Sitryx Therapeutics (“Sitryx”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases, today announced that Boehringer has acquired an exclusive license for a preclinical, small molecule program from Sitryx. The program offers a novel, oral, potentially disease-modifying treatment approach across multiple autoimmune and inflammatory disease indications.
Article content
Article content
Article content
The global burden of autoimmune and inflammatory diseases continues to rise sharply, with millions of patients unable to achieve sustainable disease control on existing therapies. This underscores the urgent need for novel, precise mechanisms that target disease‑driving pathways.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“Autoimmune and inflammatory diseases remain areas where innovation is urgently needed. Sitryx’s small molecule inhibitor program brings forward a promising new mechanism that aligns with our focus on advancing first-in-class approaches. Together with Sitryx, we are committed to translating this science into therapies that can meaningfully improve patients’ lives,” said Carine Boustany, Head of Immunology and Respiratory Diseases Research at Boehringer Ingelheim.
Article content
“This collaboration is a major milestone for our company and is a clear validation of the strength of our pipeline and our expertise translating immunometabolic targets into meaningful therapeutic candidates,” said Iain Kilty, Chief Executive Officer of Sitryx. “We are proud to out-license this preclinical program to Boehringer Ingelheim whose global capabilities in immunology and drug development will help position this program to deliver meaningful benefits to patients worldwide.”
Article content
Article content
Under the terms of the agreement, Sitryx grants Boehringer an exclusive global license to the multiple candidates and associated intellectual property within this small molecule inhibitor program. Boehringer assumes full responsibility for the program, including further research, clinical development and commercialization. Sitryx receives both upfront and near-term payments and is eligible to receive potential development, regulatory and commercialization milestone payments totaling more than $500 million, in addition to tiered royalties on future sales.
Article content
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com (Global) or https://www.boehringer-ingelheim.com/uk (UK).
English (US)